$Refractory Chronic Hand Eczema Responds to Oral Upadacitinib$

Refractory Chronic Hand Eczema Responds to Oral Upadacitinib

Saved in:

Bibliographic Details
Main Authors:	Nada Alghamdi, Abdullah AN.Aljalfan, Abdulmajeed S. Alharbi, Omar I.Alrubaish, Serene R.Almuhaidib
Format:	Article
Language:	English
Published:	Mattioli1885 2025-01-01
Series:	Dermatology Practical & Conceptual
Subjects:	Hand dermatitis, Hand Eczema, Upadacitinib, Janus kinase inhibitor.
Online Access:	https://dpcj.org/index.php/dpc/article/view/4685
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Predictive factors for responders to upadacitinib treatment in patients with atopic dermatitis
by: Teppei Hagino, et al.
Published: (2024-12-01)

Early itch relief with upadacitinib predicts later skin clearance in Atopic dermatitis
by: Teppei Hagino, et al.
Published: (2024-12-01)

Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
by: Teppei Hagino, et al.
Published: (2024-12-01)

Italian Expert Opinion on Chronic Hand Eczema: from Guidelines to Clinical Practice
by: Luca Stingeni, et al.
Published: (2024-11-01)

Successful Achievement of Demanding Outcomes in Upadacitinib-Treated Atopic Dermatitis Patients: A Real-World, 96-Week Single-Centre Study
by: Stamatios Gregoriou, et al.
Published: (2025-01-01)

A cross-sectional study of clinical characteristics and risk factors for hand eczema in the general Chinese population
by: Zilu Qu, et al.
Published: (2024-11-01)

Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study
by: Filip Van den Bosch, et al.
Published: (2025-02-01)

Efficacy and Safety of Ruxolitinib Cream in Atopic Dermatitis Based on Previous Medication History
by: Andrew Blauvelt, et al.
Published: (2024-10-01)

Development and Validation of a Patient-Reported Outcome Measure of the Impact of Chronic Hand Eczema on Health-Related Quality of Life: the Hand Eczema Impact Scale (HEIS)
by: Elke Weisshaar, et al.
Published: (2024-10-01)

Comparative study between efficacy of topical tofacitinib 2% ointment versus topical clobetasol propionate 0.05% ointment in hand eczema at a tertiary hospital in central India [version 1; peer review: 2 approved]
by: Dr Adarshlata Singh, et al.
Published: (2024-04-01)

Skin diseases among adults in Tasiilaq, East Greenland
by: Morten B. Haulrig, et al.
Published: (2024-12-01)

A Case of Upadacitinib-Associated Ileus Secondary to Psoriasis Induced by Treatment of Atopic Dermatitis with Dupilumab
by: Liu X, et al.
Published: (2024-12-01)

Amenorrhea in an Adolescent Female as a Rare Adverse Event of Upadacitinib Treatment for Atopic Dermatitis
by: Teng Y, et al.
Published: (2024-11-01)

The management of severe eczema in pregnancy
by: E Keeling, et al.
Published: (2025-01-01)

Atopic Dermatitis Treatments Before and After Initiation of Ruxolitinib Cream: 6-Month Follow-Up Analysis of a US Payer Claims Database
by: Liu J, et al.
Published: (2025-02-01)

Prevalence, severity, and risk factors of eczema among young children and adolescents in Saudi Arabia: A national cross-sectional study, 2019
by: Sawsan Al Nahas, MBBS, DFE, ABHS, et al.
Published: (2024-11-01)

Recurring eczema herpeticum complicated by herpetic meningitis and staphylococcal bacteremia
by: Morgan C. Lain, et al.
Published: (2024-06-01)

The Eczema Bathing Study: Weekly versus daily bathing for people with eczema? Protocol of an online, randomised controlled trial [version 1; peer review: 1 approved, 2 approved with reservations]
by: Paul Leighton, et al.
Published: (2024-10-01)

The Eczema Bathing Study: Weekly versus daily bathing for people with eczema? Protocol of an online, randomised controlled trial [version 2; peer review: 1 approved, 2 approved with reservations]
by: Paul Leighton, et al.
Published: (2025-01-01)

A case of refractory anti-MDA5-positive amyopathic dermatomyositis successfully treated with upadacitinib
by: Xin Huang, et al.
Published: (2024-12-01)

Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study
by: Nina Magnolo, et al.
Published: (2024-12-01)

Anti-Inflammatory Effects of Cannabigerol In Vitro and In Vivo Are Mediated Through the JAK/STAT/NFκB Signaling Pathway
by: Ga Hee Jeong, et al.
Published: (2025-01-01)

Rapid Remission With Upadacitinib in a Child With Refractory Crohn's Disease and ATM Mutation: A Case Report
by: Yan Liu, MD, et al.
Published: (2024-01-01)

A systematic review of guidelines for the management of atopic dermatitis in children
by: Maya Deva, MBBS, et al.
Published: (2024-12-01)

Response to upadacitinib monotherapy in a patient with eczematid-like pigmented purpuric dermatosis
by: Aditi Chokshi, DO, et al.
Published: (2025-02-01)

Refractory pityriasis rubra pilaris treated with abrocitinib
by: Filip Rob
Published: (2025-01-01)

Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis
by: Andrew Blauvelt, et al.
Published: (2025-12-01)

Correlation of serum Vitamin D levels and disease severity in patients with atopic dermatitis: A hospital-based, cross-sectional study from North India
by: Shreya Malhan, et al.
Published: (2024-12-01)

Subcutaneous immunotherapy in a patient taking ofatumumab for multiple sclerosis and upadacitinib for atopic dermatitis
by: Twan Sia, BA, et al.
Published: (2025-05-01)

Patients’ preferences for systemic treatment of atopic dermatitis: safety and efficacy count the most
by: Marthe-Lisa Schaarschmidt, et al.
Published: (2024-12-01)

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system
by: Shiyi Wang, et al.
Published: (2025-02-01)

Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life
by: Andrew Blauvelt, et al.
Published: (2022-07-01)

Dupilumab‐related ocular surface disorders in a paediatric cohort with atopic dermatitis, treated in a tertiary paediatric hospital in London
by: Anjali Rampersad, et al.
Published: (2024-12-01)

An Analysis of the Effectiveness and Safety of Upadacitinib in the Treatment of Inflammatory Bowel Disease: A Multicenter Real-World Study
by: Hongzhen Wu, et al.
Published: (2025-01-01)

Dual immunomodulator therapy with adalimumab and upadacitinib to treat recalcitrant hidradenitis suppurativa
by: Zahidul Islam, BA, et al.
Published: (2025-02-01)

Pupil dilation responds to the intrinsic social characteristics of affective touch
by: Greta Bonino, et al.
Published: (2024-10-01)

Upadacitinib for the management of bullous pemphigoid coexisting with psoriasis vulgaris: a case report and literature review
by: Fangying Su, et al.
Published: (2024-12-01)

Subcutaneous immunoglobulin-induced eczematous dermatitis
by: Rachel Breidbart, BS, et al.
Published: (2025-02-01)

The Association between Atopic Dermatitis Severity and Mood Disturbance among Adults: A Cross-sectional Study
by: Farah F. Albakr, et al.
Published: (2024-12-01)

A Chinese drug-compatibility-based approach to purslane hydrogels for acute eczema therapy
by: Ling Wang, et al.
Published: (2025-02-01)